Targeted Delivery of LOW-DOSE Cyclosporine
RESTASIS® Ophthalmic Emulsion―Targeted, Nonsystemic, Low-Dose Drug Delivery
- The delivery vehicle for cyclosporine in RESTASIS® is a unique, oil-based ophthalmic emulsion. This emulsion technology provides effective drug delivery to ocular tissue and is effective with a low cyclosporine concentration (0.05%)
- Since the emulsion is designed to solubilize cyclosporine, it ensures penetration into surface tissue at low cyclosporine concentrations
© 2007 Allergan, Inc. All rights reserved | Privacy Statement | FAQs | Terms of Use | Site Map
This information is intended for residents of the United States. ® and ™ marks owned by Allergan, Inc.
RESTASIS® Ophthalmic Emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.
Important Safety Information:
RESTASIS® is contraindicated in patients with active ocular infections and has not been studied in patients with a history of herpes keratitis.
The most common adverse event was ocular burning (upon instillation) – 17%. Other events reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).
Please see full prescribing information for RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%.